Treatment and control of cholangiocarcinoma (CCA): the bile duct cancer is limited by the lack of effective chemotherapeutic drugs and alternative drugs are needed, particularly those from natural sources. This article reviews steps of research and development of (Thunb) DC. (AL) as potential candidate for CCA chemotherapy, with adoption of the reverse pharmacology approach. Major steps include (1) reviewing of existing information on its phytochemistry and pharmacological properties, (2) screening of its activities against CCA, (3) standardization of AL, (4) nonclinical studies to evaluate anti-CCA activities, (5) phytochemistry and standardization of AL extract, (6) development of oral pharmaceutical formulation of standardized AL extract, and (7) toxicity testing of oral pharmaceutical formulation of standardized AL extract. Results from a series of our study confirm anti-CCA potential and safety profiles of both the crude extract and the finished product (oral pharmaceutical formulation of the standardized AL extract). Phases I and II clinical trials of the product to confirm tolerability and efficacy in healthy subjects and patients with advanced stage CCA will be carried out soon.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5733893 | PMC |
| http://dx.doi.org/10.1155/2017/5929234 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The 30-year evolution of oral cholera vaccines: A case study of a collaborative network alternative innovation model.
PLOS Glob Public Health
January 2025
Global Health Centre, Geneva Graduate Institute, Genève, Switzerland.
Cholera outbreaks have been rapidly increasing around the world. While long-term cholera prevention and control measures rely on improvements in water, sanitation, and hygiene, oral cholera vaccines (OCVs) are used for prevention and control in the short-to-medium term. OCVs lack the market incentives available in other more profitable disease areas.
View Article and Find Full Text PDFA Literature Review on Oral Lumenoscopy: A Non-invasive Method for Diagnosing Oral Potentially Malignant Disorders.
Cureus
December 2024
Oral Medicine and Radiology, SRM Kattankulathur Dental College and Hospital, SRM Institute of Science and Technology (SRMIST), Chennai, IND.
Dentistry still faces difficulties in diagnosing oral precancer and cancer, especially when it comes to early phase changes or disease detection, evaluation, and treatment. In essence, oral lumenography is the process of identifying oral lesions using a chemiluminescent light source and a toluidine blue labeling system. Since neoplastic epithelial cells have a changed nuclear-cytoplasmic ratio, acetic acid dehydration brings out this nuclear density and gives the tissue an "acetowhite" look.
View Article and Find Full Text PDFOptimizing hydrophilic drug incorporation into SEDDS using dry reverse micelles: a comparative study of preparation methods.
Drug Deliv Transl Res
January 2025
Thiomatrix Forschungs- und Beratungs GmbH, Trientlgasse 65, 6020, Innsbruck, Austria.
Aim: It was the aim of this study to compare two different dry reverse micelle (RM) preparation methods for the incorporation of hydrophilic drugs into oral self-emulsifying drug delivery systems (SEDDS).
Methods: Cationic ethacridine lactate, anionic fluorescein sodium salt and the antibiotic peptide bacitracin were solubilized in RM containing sodium docusate, soy phosphatidylcholine and sorbitan monooleate in highly lipophilic oils such as squalane. In the dry addition (DA) method, drugs were directly added to empty RM in their powder form.
Management of Recurrent Clostridioides difficile Infection (rCDI): A Systematic Literature Review to Assess the Feasibility of Indirect Treatment Comparison (ITC).
Infect Dis Ther
January 2025
Global Research and Medical, Ferring Pharmaceuticals, Kastrup, Denmark.
Recurrent Clostridioides difficile infection (rCDI) is a major cause of increased morbidity, mortality, and healthcare costs. Fecal-microbiota-based therapies are recommended for rCDI on completion of standard-of-care (SoC) antibiotics to prevent further recurrence: these therapies include conventional fecal-microbiota transplantation and the US Food and Drug Administration-approved therapies REBYOTA® (RBL) and VOWST Oral Spores™ (VOS). As an alternative to microbiota-based therapies, bezlotoxumab, a monoclonal antibody, is used as adjuvant to SoC antibiotics to prevent rCDI.
View Article and Find Full Text PDFDevelopment and in vitro/in vivo evaluation of taste-masked orodispersible films of dapoxetine hydrochloride using ion exchange resins.
Drug Deliv Transl Res
January 2025
Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410006, Hunan, China.
Dapoxetine hydrochloride tablets are the most commonly used drug for the treatment of premature ejaculation (PE). However, the tablets must be taken with water 1-3 h before sexual activity, which makes the medication intake conspicuous and inconvenient. This study aimed to develop taste-masked orodispersible films (ODFs) of dapoxetine hydrochloride using ion exchange resins.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!